Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025

On track to initiate a Phase 2 study in 1H 2026

ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care

Read more at globenewswire.com